NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Medera

Medera

Private
United StatesHealthcare & Life Scienceshttps://www.medera.bio/

Last Round

M&A

Feb 26, 2026

Est. Valuation

$100M

Total Funding Raised

$3.03M

Company Overview

Medera is a clinical-stage biopharmaceutical company that develops novel gene- and cell-based therapeutic candidates for cardiovascular, pulmonary, and vascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoveryhiPSChuman induced pluripotent stem cellpreclinical drug screeningbiotech R&Ddisease modelingorgan-on-a-chipAI drug discoverypredictive toxicologyin vitro screeningdata as a serviceDaaShigh-content screeningtranslational medicinebiopharma services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Medera Comparables

Compare Medera with similar companies based on industry and business-model similarity.

Medera comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
bit.bio
84%
Axol Bioscience
84%
Ncardia
84%

Medera Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AFeb 26, 2026
Reverse MergerSep 5, 2024
M&ANov 18, 2020
GrantJan 7, 2020
GrantJun 6, 2018
Grant
Feb 26, 2018

Key People

Founding team and executive leadership

Camie Chan

Director, Chief Financial Officer And Chief Operating Officer

Executive Team

Medera Investors

Notable investors and investment history

Medera investors
InvestorRounds
Hong Kong Science and Technology ParkPrivate Placement, VC Round
Innovation and Technology CommissionGrant
Keen Vision Acquisition CorporationReverse Merger, M&A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors increased 126% MoM, from 3.9K to 8.9K.

  • Jun 8, 2025

    Grew 21% QoQ from 14 to 17 employees.

Medera Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Medera Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Medera's valuation, stock price, and market status.

Firmographic Details

HeadquartersUnited States
Employee Range21
Year Founded2021
Last FundingFeb 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.